



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/629,892	07/29/2003	Lingyu Zhu	10173-084-999	5561
20583	7590	06/30/2005	EXAMINER	
JONES DAY 222 EAST 41ST ST NEW YORK, NY 10017				MONDESI, ROBERT B
			ART UNIT	PAPER NUMBER
				1653

DATE MAILED: 06/30/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<i>Supplemental Notice of Allowability</i>	Application No.	Applicant(s)
	10/629,892	ZHU ET AL.
	Examiner	Art Unit

Robert B. Mondesi 1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to February 25, 2005.
2. The allowed claim(s) is/are 16,17,21 and 39-68.
3. The drawings filed on _____ are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some* c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application (PTO-152)
6. Interview Summary (PTO-413),
Paper No./Mail Date _____
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Irina E. Britva on June 21, 2005.

The application has been amended as follows:

Please amend the claims accordingly:

Claim 50 (Presently amended) The pharmaceutical composition of Claim 16 wherein said non-human animal ApoA-I protein having has greater than about 60% homology with native human ApoA-I protein[.]

Claim 51 (Presently amended) The pharmaceutical composition of Claim 50 wherein said non-human animal ApoA-I protein having has greater than about 70% homology with native human ApoA-I protein.

Claim 52 (Presently amended) The pharmaceutical composition of Claim 51 wherein said non-human animal ApoA-I protein having has greater than about 80% homology with native human ApoA-I protein.

Claim 53 (Presently amended) The pharmaceutical composition of Claim 52 wherein said non-human animal ApoA-I protein having has greater than about 90% homology with native human ApoA-I protein.

Claim 61 (Presently amended) The ApoA-I protein-lipid complex of Claim 17 wherein said non-human animal ApoA-I protein having has greater than about 60% homology with native human ApoA-I protein.

Claim 62 (Presently amended) The ApoA-I protein-lipid complex of Claim 61 wherein said non-human animal ApoA-I protein having has greater than about 70% homology with native human ApoA-I protein.

Claim 63 (Presently amended) The ApoA-I protein-lipid complex of Claim 62 wherein said non-human animal ApoA-I protein having has greater than about 80% homology with native human ApoA-I protein.

Claim 64 (Presently amended) The ApoA-I protein-lipid complex of Claim 63 wherein said non-human animal ApoA-I protein having has greater than about 90% homology with native human ApoA-I protein.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert B. Mondesi whose telephone number is 571-272-0956. The examiner can normally be reached on 9am-5pm, Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Robert B. Mondesi

BBM
06-22-05



JON WEBER
SUPERVISORY PATENT EXAMINER